{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:53:54Z","timestamp":1773791634734,"version":"3.50.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cytomegalovirus (CMV) infection poses a significant risk to kidney transplant recipients. CMV immunoglobulin shows promising prophylactic effect, particularly in the context of ABO-incompatible transplants. However, its efficacy in preventing CMV viremia remains underexplored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective study, we enrolled patients who underwent ABO-incompatible living donor kidney transplantation between May 2021 and September 2023. Prophylactic CMV immunoglobulin was administered at 100 mg\/kg weekly for one month in the combined prophylaxis group, while no prophylactic medication was applied in the preemptive therapy group. The primary outcome was measured as the incidence of clinically relevant CMV viremia (CMV DNA <jats:bold>&amp;gt;<\/jats:bold>10,000 copies\/mL) within one year after transplantation. Both groups received standard preemptive therapy with ganciclovir or valganciclovir after diagnosed with clinically relevant CMV viremia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Prophylactic CMV immunoglobulin significantly reduced clinically relevant viremia incidence compared to preemptive therapy group (16.0% vs. 34.0%, P = 0.04). At the end of the follow-up, the combined prophylaxis group showed higher eGFR (56.40 \u00b1 14.19 vs. 47.30 \u00b1 13.01 mL\/min\/1.73m\u00b2, P = 0.0014) and lower serum creatinine (146.5 \u00b1 57.07 vs. 171.2 \u00b1 51.48 \u00b5mol\/L, P = 0.0274). However, no significant differences in renal function were observed between the groups at1,3, or 6 months post-transplantation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CMV immunoglobulin represents a promising prophylactic option for reducing clinically relevant CMV viremia incidence and delaying infection onset in ABO-incompatible kidney transplant recipients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1562951","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T04:13:21Z","timestamp":1745813601000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of prophylactic cytomegalovirus immunoglobulin on cytomegalovirus viremia and graft function in ABO-incompatible living donor kidney transplantation: a retrospective analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Linhong","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongping","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjia","family":"Di","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: A randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100585","DOI":"10.1016\/j.trre.2020.100585","article-title":"Organ donation in the US and Europe: The supply vs demand imbalance","volume":"35","author":"Lewis","year":"2021","journal-title":"Transplant Rev (Orlando)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00234","article-title":"ABO-incompatible kidney transplantation","volume":"8","author":"Morath","year":"2017","journal-title":"Front In Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.0895","article-title":"Safety and efficacy of antiviral therapy for prevention of cytomegalovirus reactivation in immunocompetent critically ill patients: A randomized clinical trial","volume":"177","author":"Cowley","year":"2017","journal-title":"JAMA Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00746-1","article-title":"New insights on CMV management in solid organ transplant patients: prevention, treatment, and management of resistant\/refractory disease","volume":"12","author":"Kotton","year":"2023","journal-title":"Infect Dis Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.09.010","article-title":"American Society for Transplantation and Cellular Therapy Series: 4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation","volume":"27","author":"Yong","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13616","article-title":"Economic impacts of ABO-incompatible live donor kidney transplantation: A national study of medicare-insured recipients","volume":"16","author":"Axelrod","year":"2016","journal-title":"Am J Transplant"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e00043-19","DOI":"10.1128\/CMR.00043-19","article-title":"Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation","volume":"34","author":"Limaye","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198710223171703","article-title":"Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients","volume":"317","author":"Snydman","year":"1987","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat0066","article-title":"Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation","volume":"363","author":"Martins","year":"2019","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz596","article-title":"Cytomegalovirus humoral response against epithelial cell entry-mediated infection in the primary infection setting after hematopoietic cell transplantation","volume":"221","author":"Zamora","year":"2020","journal-title":"J\u00a0Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.927420","article-title":"Acute rejection and infectious complications in ABO- and HLA-incompatible kidney transplantations","volume":"25","author":"Ko","year":"2020","journal-title":"Ann Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12786","article-title":"Quantifying the risk of incompatible kidney transplantation: a multicenter study","volume":"14","author":"Orandi","year":"2014","journal-title":"Am J Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2014.75","article-title":"The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies","volume":"12","author":"Wills","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14070","article-title":"Epidemiology, management, and burden of cytomegalovirus in solid organ transplant recipients in selected countries outside of Europe and North America: A systematic review","volume":"25","author":"Silva Junior","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cmi.2022.07.001","article-title":"Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium","volume":"29","author":"Khawaja","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1189","article-title":"Immunosuppressive agents and infectious risk in transplantation: managing the \u201cNet state of immunosuppression","volume":"73","author":"Roberts","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.05.008","article-title":"Opportunistic infections in transplant patients","volume":"33","author":"Kumar","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw017","article-title":"The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation","volume":"31","author":"Lee","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.623178","article-title":"Case report: management of a multidrug-resistant CMV-strain in a renal transplant recipient by high-dose CMV-specific immunoglobulins, modulation in immunosuppression, and induction of CMV-specific cellular immunity","volume":"11","author":"Wiening","year":"2020","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-023-03934-1","article-title":"Incidence of postoperative cytomegalovirus and BK-polyoma virus infections and graft loss in ABO-incompatible renal transplant recipients: a multicenter retrospective study","volume":"56","author":"Kodama","year":"2024","journal-title":"Int Urol Nephrol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001095","article-title":"The immunology of posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV","author":"Carbone","year":"2016","journal-title":"Transplantation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e781","DOI":"10.1097\/TXD.0000000000001236","article-title":"Stimulatory effect of CMV immunoglobulin on innate immunity and on the immunogenicity of CMV antigens","volume":"7","author":"Deml","year":"2021","journal-title":"Transplant Direct"},{"key":"B27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/life12030361","article-title":"Effectiveness of prophylactic human cytomegalovirus hyperimmunoglobulin in preventing cytomegalovirus infection following transplantation: A systematic review and meta-analysis","volume":"12","author":"Barten","year":"2022","journal-title":"Life (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e01794-16","DOI":"10.1128\/AAC.01794-16","article-title":"Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients","volume":"61","author":"Ishida","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa249","article-title":"Cytomegalovirus after kidney transplantation in 2020: moving towards personalized prevention","volume":"37","author":"Hellemans","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1190794","article-title":"Long-term CMV monitoring and chronic rejection in renal transplant recipients","volume":"13","author":"Ishikawa","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015050523","article-title":"B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome","volume":"27","author":"Colucci","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","article-title":"B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients","volume":"19","author":"Thiel","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfx038","article-title":"Infectious complications of rituximab therapy in renal disease","volume":"10","author":"Nixon","year":"2017","journal-title":"Clin Kidney J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686271","article-title":"Current approaches to desensitization in solid organ transplantation","volume":"12","author":"Schinstock","year":"2021","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002639","article-title":"Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: A consecutive series of 15 cases","volume":"103","author":"Tan","year":"2019","journal-title":"Transplantation"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2019.12.002","article-title":"Complement-based therapy in the management of antibody-mediated rejection","volume":"27","author":"Bhalla","year":"2020","journal-title":"Adv Chronic Kidney Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1562951\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T04:13:22Z","timestamp":1745813602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1562951\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2025.1562951"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1562951","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"article-number":"1562951"}}